Genetic engineering is the foundational discipline upon which modern synthetic biology is built. Beginning with the development of recombinant DNA technology in the 1970s by researchers like Stanley Cohen and Herbert Boyer, the field enabled scientists to cut and paste DNA sequences between organisms for the first time. This breakthrough led to the first genetically engineered products, including recombinant human insulin produced by Genentech in 1982, which transformed the treatment of diabetes worldwide.
Today, genetic engineering encompasses a broad toolkit of techniques ranging from classical restriction enzyme cloning to sophisticated CRISPR-based editing systems. Companies like Twist Bioscience provide the synthetic DNA that serves as raw material for genetic engineering projects, while platform companies like Ginkgo Bioworks apply automated genetic engineering at industrial scale. The precision of modern tools has expanded from simple gene insertions to complex multi-gene pathway engineering, enabling the construction of microbial cell factories that produce everything from pharmaceuticals to sustainable aviation fuel.
The regulatory landscape for genetic engineering continues to evolve as the technology matures. The USDA, FDA, and EPA coordinate oversight of genetically engineered organisms in the United States, while the European Union maintains a distinct framework. Recent developments in gene editing have prompted regulators worldwide to reconsider whether organisms modified through precise edits, without introducing foreign DNA, should be regulated differently from traditional transgenic organisms.